Q&A with Richard Shor, President of SaniSure - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Richard Shor, President of SaniSure
Q&A with Richard Shor, President of SaniSure.

Pharmaceutical Technology
Volume 36, Issue 12


Richard Shor

PharmTech:

How has the increasing focus on biopharmaceuticals affected your business?

Shor:

In the sense that biopharmaceuticals are now a growth industry as opposed to the traditional chemical–pharmaceutical industry, it has impacted us greatly. Single-use process components are ideal for the biopharmaceutical arena. Batches are typically smaller and most of the processes are not using chemicals that will affect the components we provide.

PharmTech:

How will the industry remain innovative as it reduces spending on research?

Shor:

We have not seen any decline in innovations; however, it is now coming from other sources. What we are seeing is the partnership and licensing of a molecule to a start-up or small biotechnology company. This model allows the big companies to reduce their R&D budgets and risk exposure while allowing the smaller companies to get funding through private equity or other sources. If the product is a success, the investors win as well as the large biotechnology companies that will purchase the smaller company in the end.

PharmTech:

Do you see a new industry trend emerging?

Shor:

Regulatory compliance has become a big part of our customers' requirements. Biotechnology companies are demanding much tighter control and assurance of our products. As a supplier of single-use components and systems, SaniSure is now being asked to have control of our supplier base and the raw materials they are using. The onus is on us to assure a consistent and stable level of quality and control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here